Deutsche Bank AG Increases Stake in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Deutsche Bank AG lifted its position in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL - Free Report) by 12.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 84,163 shares of the specialty pharmaceutical company's stock after purchasing an additional 9,164 shares during the period. Deutsche Bank AG owned about 0.26% of Collegium Pharmaceutical worth $2,411,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds also recently made changes to their positions in COLL. Barclays PLC boosted its position in Collegium Pharmaceutical by 152.2% during the 3rd quarter. Barclays PLC now owns 75,052 shares of the specialty pharmaceutical company's stock worth $2,899,000 after buying an additional 45,291 shares during the period. Nisa Investment Advisors LLC raised its stake in shares of Collegium Pharmaceutical by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company's stock valued at $71,000 after acquiring an additional 316 shares during the last quarter. Exchange Traded Concepts LLC lifted its holdings in shares of Collegium Pharmaceutical by 4.7% during the fourth quarter. Exchange Traded Concepts LLC now owns 75,095 shares of the specialty pharmaceutical company's stock worth $2,151,000 after purchasing an additional 3,402 shares during the period. KBC Group NV grew its stake in shares of Collegium Pharmaceutical by 72.5% in the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company's stock worth $67,000 after purchasing an additional 982 shares during the last quarter. Finally, Caprock Group LLC increased its holdings in Collegium Pharmaceutical by 6.7% in the fourth quarter. Caprock Group LLC now owns 8,698 shares of the specialty pharmaceutical company's stock valued at $249,000 after purchasing an additional 543 shares during the period.

Analyst Ratings Changes

COLL has been the topic of a number of research analyst reports. Wall Street Zen cut shares of Collegium Pharmaceutical from a "strong-buy" rating to a "buy" rating in a research report on Saturday, April 19th. Needham & Company LLC reissued a "buy" rating and issued a $46.00 price objective on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. HC Wainwright restated a "buy" rating and set a $50.00 price objective on shares of Collegium Pharmaceutical in a report on Monday, March 24th. Finally, Piper Sandler reiterated a "neutral" rating and issued a $37.00 target price (up from $36.00) on shares of Collegium Pharmaceutical in a report on Friday, May 9th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, Collegium Pharmaceutical presently has a consensus rating of "Moderate Buy" and an average price target of $43.80.

Collegium Pharmaceutical Stock Performance

COLL traded up $0.62 on Tuesday, hitting $29.48. The company's stock had a trading volume of 268,741 shares, compared to its average volume of 427,338. The company's 50 day simple moving average is $28.08 and its 200-day simple moving average is $29.65. The company has a quick ratio of 0.88, a current ratio of 0.97 and a debt-to-equity ratio of 3.43. Collegium Pharmaceutical, Inc. has a 12 month low of $23.23 and a 12 month high of $42.29. The firm has a market cap of $947.25 million, a P/E ratio of 12.71 and a beta of 0.63.

Collegium Pharmaceutical (NASDAQ:COLL - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The specialty pharmaceutical company reported $1.49 earnings per share for the quarter, missing the consensus estimate of $1.50 by ($0.01). The company had revenue of $177.76 million during the quarter, compared to analysts' expectations of $174.96 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. Collegium Pharmaceutical's revenue for the quarter was up 22.7% compared to the same quarter last year. During the same quarter last year, the firm posted $1.45 earnings per share. Analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 EPS for the current year.

Insider Activity at Collegium Pharmaceutical

In other Collegium Pharmaceutical news, CFO Colleen Tupper sold 1,949 shares of the firm's stock in a transaction on Thursday, March 6th. The shares were sold at an average price of $30.00, for a total value of $58,470.00. Following the completion of the transaction, the chief financial officer now directly owns 177,195 shares of the company's stock, valued at $5,315,850. This trade represents a 1.09% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total value of $1,123,200.00. Following the completion of the transaction, the executive vice president now directly owns 154,204 shares in the company, valued at approximately $4,330,048.32. This represents a 20.60% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 81,693 shares of company stock valued at $2,334,994. Corporate insiders own 2.51% of the company's stock.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.